Celltrion Pharmaceutical's Q2 Revenue of KRW 131.3 Billion...Highest Performance Ever
Aug 14, 2025
|
Celltrion Pharmaceutical announced on the 14th that its sales as of the second quarter of this year increased 12.1% year-on-year to 131.3 billion won. Operating profit rose 64.8% year-on-year to 15.5 billion won, and the operating profit ratio also rose more than 4%p to 11.8%. In the first half of this year, cumulative sales were KRW 243.82 billion and operating profit was KRW 26.25 billion, up 13.9% and 100.3% from the same period last year, respectively.
In the chemical business division, sales of 66.3 billion won were made, with the existing main product, the soy sauce solvent 'Godex', growing 6.9% year-on-year to KRW 16 billion, and the hypertension drug 'Dilatren' growing 7% to KRW 15.1 billion. The diabetes drug 'Nessina', which has completed production internalization, recorded sales of 6.4 billion won, up 65.7% from the same period last year, resulting in a significant sales growth. In addition, diabetes drugs 'Actos' and hypertension drugs 'Dalbi' achieved sales of KRW 1.8 billion and KRW 2.7 billion, respectively.
In the biosimilar business sector, sales rose 58.3% year-on-year to 32.5 billion won, continuing solid growth. Among them, autoimmune disease drug 'Ramsima', breast cancer and gastric cancer drug 'Herzuma', and blood cancer drug 'Truxima' achieved a total sales of KRW 18.8 billion, while autoimmune disease drug 'Uplima' grew 129.4% year-on-year to KRW 1.8 billion, and anti-cancer drug 'Vegzelma' grew 125.5% to KRW 2 billion.
New biosimilar products released this year also helped increase sales. Sales of new biosimilars such as autoimmune disease treatment 'Stekima', eye disease treatment 'Idenzelt', allergic asthma treatment 'Omriclo', and bone disease treatment 'Stoboclo-Ossenbelt' recorded a total of 9.7 billion won in sales.
In the consignment production sector, sales rose 24.6% year-on-year to 23.2 billion due to increased commercial production of PFS (precharged syringe, prefilled syringe) products such as autoimmune disease drugs 'Ramsima SC' and 'Euplima'.
A representative from Celltrion Pharmaceuticals said "We achieved the largest second quarter of all time thanks to solid growth in existing products and full-scale sales of new products."We will continue to do our best to strengthen the sales competitiveness of our flagship products based on a stable production base."."
This article was translated by Naver AI translator.
